"Ganciclovir" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An ACYCLOVIR analog that is a potent inhibitor of the Herpesvirus family including cytomegalovirus. Ganciclovir is used to treat complications from AIDS-associated cytomegalovirus infections.
| Descriptor ID |
D015774
|
| MeSH Number(s) |
D03.633.100.759.758.399.454.250.300
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Ganciclovir".
Below are MeSH descriptors whose meaning is more specific than "Ganciclovir".
This graph shows the total number of publications written about "Ganciclovir" by people in this website by year, and whether "Ganciclovir" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 0 | 1 | 1 |
| 1997 | 1 | 1 | 2 |
| 1998 | 0 | 1 | 1 |
| 1999 | 1 | 0 | 1 |
| 2000 | 3 | 1 | 4 |
| 2001 | 0 | 1 | 1 |
| 2002 | 1 | 0 | 1 |
| 2004 | 1 | 1 | 2 |
| 2010 | 0 | 1 | 1 |
| 2012 | 1 | 0 | 1 |
| 2013 | 1 | 0 | 1 |
| 2014 | 0 | 2 | 2 |
| 2017 | 1 | 1 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Ganciclovir" by people in Profiles.
-
Fleming JN, Taber DJ, Weimert NA, Nadig S, McGillicuddy JW, Bratton CF, Baliga PK, Chavin KD. Valganciclovir (VGCV) followed by cytomegalovirus (CMV) hyperimmune globulin compared to VGCV for 200 days in abdominal organ transplant recipients at high risk for CMV infection: A prospective, randomized pilot study. Transpl Infect Dis. 2017 Dec; 19(6).
-
Halliday M, Ross J, Southgate WM. Cytomegalovirus-Induced Hemophagocytic Lymphohistiocytosis in an Extreme Preterm Infant: Recognition and Therapy Leading to Recovery. Adv Neonatal Care. 2017 Apr; 17(2):91-95.
-
Byrns JS, Pilch NW, Taber DJ. Impact of Pharmacist Involvement in Early Identification and Enrollment in Patient Assistance Programs on CMV Outcomes in Transplantation. J Pharm Pract. 2016 Apr; 29(2):97-102.
-
Miller PE, Gelber AC, Houston BA. Abdominal pain, fever, and unrelenting melena. Gastroenterology. 2014 Jun; 146(7):1606-7.
-
Posadas Salas MA, Taber DJ, Chua E, Pilch N, Chavin K, Thomas B. Critical analysis of valganciclovir dosing and renal function on the development of cytomegalovirus infection in kidney transplantation. Transpl Infect Dis. 2013 Dec; 15(6):551-8.
-
Moss HB, Chavala S, Say E, Miller MB. Ganciclovir-resistant cytomegalovirus (CMV) retinitis in a patient with wild-type CMV in her plasma. J Clin Microbiol. 2012 May; 50(5):1796-9.
-
McGillicuddy JW, Weimert NA, Taber DJ, Turner A, Mitchell LA, Wray DW, Egidi MF, Kuppachi S, Hughes MG, Baliga PK, Chavin KD. Can preemptive cytomegalovirus monitoring be as effective as universal prophylaxis when implemented as the standard of care in patients at moderate risk? Transplantation. 2010 May 27; 89(10):1218-23.
-
Borucki MJ, Spritzler J, Asmuth DM, Gnann J, Hirsch MS, Nokta M, Aweeka F, Nadler PI, Sattler F, Alston B, Nevin TT, Owens S, Waterman K, Hubbard L, Caliendo A, Pollard RB. A phase II, double-masked, randomized, placebo-controlled evaluation of a human monoclonal anti-Cytomegalovirus antibody (MSL-109) in combination with standard therapy versus standard therapy alone in the treatment of AIDS patients with Cytomegalovirus retinitis. Antiviral Res. 2004 Nov; 64(2):103-11.
-
Taber DJ, Ashcraft E, Baillie GM, Berkman S, Rogers J, Baliga PK, Rajagopalan PR, Lin A, Emovon O, Afzal F, Chavin KD. Valganciclovir prophylaxis in patients at high risk for the development of cytomegalovirus disease. Transpl Infect Dis. 2004 Sep; 6(3):101-9.
-
Mercer KE, Ahn CE, Coke A, Compadre CM, Drake RR. Mutation of herpesvirus thymidine kinase to generate ganciclovir-specific kinases for use in cancer gene therapies. Protein Eng. 2002 Nov; 15(11):903-11.